by multiparametric flow cytometry (MFC) to monitor treatment efficiency is one of the greatest challenges in the treatment of AML. Recently, we reported a reliable method by MFC to quantify three hematopoietic progenitor populations and the putative LSC compartment by using a combination of antibodies at diagnosis and follow-up. 11 However, these markers are not always enough to target LSCs and new strategies are needed, even in conventional MRD by MFC based on leukemia-associated immunophenotypes (LAIP). CD9 antigen belongs to the tetraspanin family, which are cell surface proteins clustering in membrane entities called tetraspanin-enriched microdomains (TEMs). 12 Tetraspanins contribute to numerous cellular process as cell adhesion, cell activation, or proliferation and have been implicated in several carcinogenous processes such as angiogenesis or metastasis in human cancers. 13 Among them, CD9 was first known as a tumor suppressor but several studies showed its oncogenic and prometastatic functions, [14] [15] [16] suggesting that the different partners of CD9 in TEMs could explain these different roles.
In hematological malignancies, CD9 has been mainly studied in acute lymphoblastic leukemia (ALL) where it might promote cancer stem cell-like properties and dissemination of the disease with CXCR4-mediated migration. 17, 18 Its role in AML remains controversial:a few studies suggested a pejorative role of CD9 with a decreased OS 19 and a negative association with t(8;21)(q22;q22) 20 while another study showed a correlation between CD9 and mutated NPM1 AML 21 which are associated with a favorable prognosis. Here, we analyzed the expression of CD9 on AML primary cells and physiologic progenitors, the prognostic role of CD9 on survival in AML patients treated with intensive chemotherapy, its association with classical biological factors and its usefulness to discriminate LSCs from HSCs.
| MATERIALS AND METHODS

| Patients
One hundred and twelve patients with AML de novo diagnosed between 2009 and 2016 and treated with intensive chemotherapy were included in this study. Patients with acute promyelocytic leukemia were excluded. Patients were treated with induction chemotherapy (continuous infusion of cytarabine for 7 days with daunorubicin or idarubicine for 3 days) and at least two consolidation courses after complete remission (CR). High-risk cases (unfavorable cytogenetic or combined genetic risk, patients with early relapse…) underwent hematopoietic stem cell transplantation (HSCT). All patients were treated in the department of Hematology of Lille hospital. Signed informed consent was obtained from each patient in accordance with the declaration of Helsinki. Cytogenetic and molecular risks and CR criteria were determined according to European Leukemia Net recommendations. The gating strategy for flow cytometry analysis was then performed as described previously. 11 Briefly, blast cells were gated as CD45dim/SSClow population and hematogones (CD38++CD19+ phenotype) were excluded from this gate using these two antibodies. CD34 and CD38 positivity were preset on this population and then, P6 (CD34+CD38−), P7 (CD34+CD38dim), and P8 (CD34+CD38+) populations were determined within blast cells. Finally, from the P6 gated cells, the different progenitor populations were determined using CD90 and CD45RA expression.
| Statistical analysis
Comparison of CD9 expression and CD9 mean fluorescence intensity (MFI) between AML bone marrows, normal bone marrows, and hematogones was assessed by Kruskal-Wallis nonparametric test. Differences between the patients negative and positive for CD9 (ie, less or more than 20% of expression on blast cells) on quantitative variables were assessed by Student t test and qualitative variables were compared using chi-square test. Quantitative variables associated with either OS, event-free survival (EFS), and relapse-free survival (RFS) were tested with the Cox model. OS, EFS, and RFS were then described by the Kaplan-Meier method. For patients who underwent BM transplantation, survival was censored at the date of transplantation and for patients alive, survival was censored at the date of last known alive. Multivariate analysis was performed with a Cox method:hazard ratios were adjusted on variables with significant pronostic value (P < 0.05) for EFS, OS, and RFS.
A P-value < 0.05 (two-tailed) was considered statistically significant. Statistical analysis was performed using SPSS 22.0 software (IBM, New York, USA).
| RESULTS
| CD9 expression on normal and leukemic cells
CD9 expression was observed on monocytes on normal BM and normal peripheral blood, and absence of CD9 expression was observed on granulocytes as previously reported ( Figure 1A ). 23 We analyzed CD9 expression on normal he- Figure 1B) . A significant higher expression of CD9 was found on malignant blast cells compared to physiologic myeloblasts considering percentages of expression and MFI levels ( Figure 1C , KruskalWallis nonparametric test P < 0.001). Thus, we could consider expression of CD9 as a frequent leukemia-associated immunophenotype (LAIP) in our study.
| CD9 and prognostic factors in AML
One hundred and twelve patients were included in our study with ages ranging from 21 to 78 years. First, we observed three types of CD9 expression profile:weak or negative (Figure 2A ), intermediate with heterogeneous positive expression ( Figure 2B ) and strong and homogenous expression ( Figure 2C ). Then, we compared patient characteristics according to CD9 expression ( classical LAIP (CD7 expression, lack of CD13/CD33 expression, CD33 overexpression…).
| Prognostic role of CD9 in AML
We used univariate analysis to evaluate the following parameters for EFS, OS, and RFS: age, WBC count, hemoglobin level, platelet count, cytogenetic risk group, FLT3-ITD status, NPM1 mutational status, and CD9 expression. A multivariate model for EFS, OS, and RFS was used for all variables with a P-value < 0.05. All the results are summarized in Table 2 . As expected, cytogenetics was the most powerful variable (P < 0.001) for EFS, OS, and RFS.
For EFS, in univariate analysis, age (P = 0.01), cytogenetic risk (P < 0.001), FLT3-ITD (P = 0.004), and CD9 expression (P = 0.009) ( Figure 3A ) had a significant prognostic role. In our multivariate model, only FLT3-ITD (P = 0.001), cytogenetic risk (P < 0.001), and CD9 expression (P = 0.004) were independent prognostic factors: CD9 expression on blast cells positively affected EFS, especially for CN-AML patients (data not shown).
For OS, in univariate analysis, CD9 expression on blast cells had no significant impact (P = 0.16) ( Figure 3B ).
For RFS, in univariate analysis, age (P = 0.004), WBC count (P = 0.02), cytogenetic risk (P = 0.001), FLT3-ITD (P = 0.003), and CD9 expression (P = 0.048) (Figure 3C ) had significant prognostic value. In our multivariate model, only WBC count had no significant value but CD9 positivity did (P = 0.039).
On the contrary, CD9 MFI had no impact on survival (EFS: P = 0.92; OS: P = 0.98, RFS; P = 0.16).
Then, percentage of CD9-positive cells was associated in this study with significant better EFS and RFS in univariate and multivariate analyses.
| CD9 is expressed on LSC and not on the more immature progenitors
We then investigated CD9 expression on normal hematopoietic progenitors (HSCs) and on their leukemic counterparts (LSCs) to use CD9 as a marker of MRD in the most immature compartment. We studied progenitor cell populations based on the expression of the following antigens: HSC (CD34+CD38−CD45RA−CD90+), Multipotent Progenitors (MPP: CD34+CD38−CD45RA−CD90dim), LymphoidPrimed Multipotent Progenitors (LMPP: CD34+CD38− CD45RA+CD90−), and the putative LSCs (CD34+CD38−) which harbored various patterns of expression of CD90 and CD45RA. 10 These phenotypic definitions of progenitor cells have been previously verified in functional assays.
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CD9 expression on these populations was studied in 17 normal BM and 17 BM from CD9+ AML patients. Interestingly, the expression of CD9 was always positive on LSCs and always negative on HSCs from normal BM (Figures 4 and 5A) . We observed a similar CD9 MFI level on LSC compared to AML blast cells (MFI on LSCs, median = 76 and MFI on blast cells, median = 66, P = 0.11, Figure 5A ). On normal bone marrow progenitors, CD9 appeared at the MPP stage and was observed on LMPP with similar MFI values ( Figure  5A ). Nevertheless, the percentage of CD9-positive cells was higher at the LMPP stage ( Figure 5B ). On the contrary, CD9
expression and CD9 MFI were steady in all AML subcompartments such as CD34+CD38− (P6), CD34+CD38dim (P7), and CD34+CD38+ (P8) AML cells ( Figure 5C,D) . 
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| DISCUSSION
Acute myeloid leukemia is an aggressive condition and chemotherapy regimens need to be adapted to the patient's disease. New prognostic tools are then important, especially for CN-AML patients, to refine the prognosis. One of the most interesting measurement of treatment response is MRD monitoring. Detection by MFC of markers expressed in blast cells is one of the most studied field over the past few years but identification of a cell antigen only expressed in AML (and not in physiologic myeloblasts) has not been successful so far. In our study, CD9 is expressed in 40% of AML and, considering its expression at a significant level on LSCs, it should be investigated when these cells are studied by the MRD strategy that we described previously. 11 In ALL, CD9
seems to be associated with cancer stem cell properties too and is involved in leukemic progression. 25 Interestingly, CD9
antigen level of expression is identical between LSCs and AML blast cells and is not expressed on normal HSCs. These findings are particularly relevant as the majority of antigens associated with LSCs (ie, TIM3, CLL1, and CD244) are less expressed on these cells compared to bulk cells and are frequently coexpressed on normal HSCs and progenitors. 26 Recently, Coustan-Smith et al published a study on MRD monitoring in AML by MFC and, interestingly, they found an overexpression of CD9 on blast cells (in 30% of AML cases) compared to physiologic myeloblasts. 27 Furthermore, they showed that CD9 was abnormally overexpressed on CD34+CD38− AML cells at diagnosis and relapse of 10 paired samples, thus corroborating the MFC strategy on LSCs that we used in this study. We investigated CD9 expression on progenitors from 17 normal BM and 17 AML BM so to strengthen the conclusions on LSCs, more AML, and normal samples, need to be studied. With these first results, targeting CD9 in AML seems to be an interesting approach to eliminate LSCs and prevent relapses with monoclonal antibodies or even chimeric antigen receptor (CAR) T-cell therapy. Anti-CD9 has already been used in vitro and could induce apoptosis of Jurkat cells and inhibition of proliferation of B-ALL cells. 25, 28 CD9 is also widely expressed on monocytes and depletion of these cells could be interesting in AML as they are implicated in disease progression by producing interleukin-1.
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In our study, we demonstrated a favorable role of CD9 on AML prognosis, especially on EFS and RFS in univariate and multivariate analyses. This favorable role was related to the percentage of CD9+ blast cells but was not highlighted according to the MFI values. Some of the patients in this cohort had a weak (higher than granulocytes) but uniform expression of CD9 and then, were considered CD9 positive. Conversely, in other patients, a few blast cells had a bright CD9 MFI but were considered CD9 negative because of the small number of those cells. Therefore, the density of CD9 antigen at cell surface is not directly linked to RFS or EFS. However, the expression of CD9 on blast membranes reflects probably changes in the cellular properties of these cells. How this expression could participate to a better chemosensitivity should be investigated (tetraspanin molecules have been largely reported to participate to various cellular processes like cell domiciliation or quiescence which could be related to this chemosensitivity).
Furthermore, this is a retrospective study and the prognostic value of CD9 needs to be determined on larger cohorts in prospective studies.
Liu et al showed a significant expression of CD9 in AML with NPM1 mutation and, therefore, a favorable prognosis, which is consistent with our findings. In contrast, CD9 seems to be associated with a worse prognosis in ALL treated with intensive chemotherapy, as it was demonstrated in a cohort of 87 patients. 30 These different results are probably explained by the association of CD9 in TEMs with different partners in ALL and AML. It could be interesting to characterize these partners and then, study the functional role of CD9 in AML.
In conclusion, CD9 is abberantly expressed of 40% of AML in our study and is associated with favorable outcome. Furthermore, this marker is expressed on LSCs and not on HSCs when the blast cells are CD9 positive. It would be of interest to perform MRD with the LSC targeting that we used here in prospective studies to better assess treatment response and then, to predict relapse.
